Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Key Inclusion Criteria: * Diagnosis of symptomatic VVC with microscopic examination with KOH positive for yeast and normal vaginal pH. * History of 3 or more episodes of VVC in the past 12 months. * Culture confirmation and resolution of the signs and symptoms of the initial VVC episode (with treatment). * Able to take oral tablets and capsules. Key exclusion Criteria: * Vaginal conditions other than recurrent VVC that may interfere with the diagnosis or evaluation of response to therapy. * Recent use of systemic and/or topical vaginal antifungal products. * Pregnant. * History of major system organ disease.